Kornimate/medical-research-clean huggingface dataset:
online survey on computer password usage.

Conditions: Carpal Tunnel Syndrome

Summary: researchers at towson university are conducting a study of computer password behaviors among users who have difficulty using their hands and arms (e.g., individuals with carpal tunnel syndrome, high level spinal cord injuries, etc.). volunteers are needed to take a short 5-10 minute online survey. the survey is completely confidential and anonymous. if you would like to participate, please visit the url below. thank you. http://pages.towson.edu/jdarcy/securitysurvey.htm

two researchers from the department of computer \& information sciences at towson university are seeking individuals who have difficulty using their hands and arms (e.g., as result of carpal tunnel syndrome, high level spinal cord injuries, etc.) to participate in a survey. the survey should take approximately 10 minutes to complete and all responses will remain completely confidential and anonymous. the purpose of the survey is to gain insight into the computing behaviors of individuals with upper-body motor impairments. we expect that the results will help researchers and system developers create more effective access control techniques to meet the special needs of this user population. the results should also assist employers in providing improved technical and procedural support to computer users that have difficulties using standard input devices. if you would like to take the online survey, please go to the following link: http://www.towson.edu/cosc/securitysurvey if you prefer a paper version of the survey, please send us an e-mail that contains your mailing address and we will send the survey to you. contact information: john d'arcy, ph.d. (jdarcy@towson.edu) jinjuan feng, ph.d. (jfeng@towson.edu) department of computer \& information sciences towson university 7800 york road towson, md 21252 u.s.a.

Eligibility criteria:
inclusion criteria: * users who have difficulty using their hands or arms exclusion criteria: -
study to evaluate the safety of rotarix™ in chinese children

Conditions: Infections, Rotavirus

Summary: the purpose of this study is to assess the safety of rotarix ™ when administered in healthy children aged 2 to 6 years in china.


Eligibility criteria:
inclusion criteria: * subjects who the investigator believes that their parents/guardians (legally acceptable representative) can and will comply with the requirements of the protocol should be enrolled in the study. * a male or female subject of chinese origin, between, and including, 2 and 6 years of age at the time of vaccination. * written informed consent obtained from the parent or legally acceptable representative of the subject. * healthy subjects as established by medical history and clinical examination before entering into the study. exclusion criteria: * use of any investigational or non-registered product other than the study vaccine within 30 days preceding the study vaccine, or planned use during the study period. * chronic administration of immunosuppressants or other immune-modifying drugs six months prior to the vaccine dose. * planned administration/administration of a vaccine not foreseen by the study protocol within 14 days of the human rotavirus vaccine or placebo with the exception of the routine childhood vaccines. routine childhood vaccines must not be administered on the same day as the human rotavirus vaccine or placebo. * administration of immunoglobulins and/or any blood products since birth within three months preceding the study vaccine or planned administration during the study period. * major congenital defects or serious chronic illness. * any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination. * history of intusussception or any chronic gastrointestinal disease that would predispose for intusussception including any uncorrected congenital malformation of the gastrointestinal tract. * history of allergic disease or reactions likely to be exacerbated by any component of the vaccine. * acute disease at the time of enrolment. * gastroenteritis within 7 days preceding the study vaccine or placebo administration. * concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product.. * child in care.

Keywords: human rotavirus vaccine
swallowing pattern of patients with nasopharyngeal cancer before and after radiation therapy: longitudinal study and correction with saliva amount

Conditions: Nasopharyngeal Carcinoma

Summary: significant evidence has shown that radiation therapy for patients with nasopharyngeal cancer (npc) can cause swallowing abnormality. based on our prior cross-sectional study for 184 npc patients from 1995 to 1999, the findings of videofluoroscopic swallowing study (vfss) revealed continuous deterioration of swallowing function of these patients even many years after radiation. we conducted a prospective study to evaluate the longitudinal change of swallowing function based on vfss before, one month, one year and two years after completing radiation therapy. the amount of saliva was measured at the same time of vfss study to test the relationship of decreased amount of saliva and swallowing function. comparison of serial vfss studies in npc patients (n=84) and normal volunteers (n=38) were obtained. we assume that this study may reveal a complete understanding of changing swallowing patterns in the course of radiation therapy of patients with npc. from this study, npc patients can understand their own swallowing function. therefore, the information may enable for earlier intervention of swallowing training or correction to avoid morbidity of radiation therapy in this patient group.


Eligibility criteria:
inclusion criteria: nasopharyngeal cancer patients \> 20 yrs. exclusion criteria: pregnant women

Keywords: nasopharyngeal carcinoma saliva swallowing videofluoroscopy radiation
curcumin in advanced cervical cancer

Conditions: Cervical Cancer, Stage IIB

Summary: determine the efficacy and safety of turmeric in the treatment of patients with advanced cervical cancer. efficacy will be determined through radiological and histopathological criteria through the rate of response to treatment, duration of response, the rate of objective response and disease control, as well as overall survival and disease-free survival. the safety of therapy will be evaluated according to the common terminology criteria for adverse events (ctcae) classification

a placebo-controlled phase ii clinical trial will be developed in patients with advanced cervical cancer who have an indication for radiotherapy. those who accept to participate will receive the standard treatment with established chemo-radiation and will be randomized in two arms, the experimental will receive 500mg of the commercial presentation (curcugreen) c / 6h vo x 16 weeks and the control arm will receive placebo. the operative hypotheses are: the addition of curcumin to the treatment improves the cumulative probability of 3-year overall survival by 20% and improves the treatment response rate. the statistical analysis will include a cox proportional hazards model and the results of the groups will be compared with the student's t-test or anova. this research hopes to collect tissue samples for future research that allows the identification of predictive biomarkers and disease prognoses.

Eligibility criteria:
inclusion criteria: women aged 18 years or older * voluntary acceptance of participation and signing of informed consent * radiotherapy indication * histological confirmation of squamous cervical cancer or histologically confirmed adenocarcinoma * stage iib - vat * chemo-radiation indication with cisplatin, cisplatin/fluorouracil, carboplatin (if cisplatin intolerant) * ecog equal to or less than 1 and a karnofsky index equal to or greater than 70%. exclusion criteria: * being pregnant or breastfeeding * presence of second concomitant neoplasia * any previous surgical, radiotherapy or chemotherapy treatment. * diagnosis of invasive recurrent carcinoma of the cervix * receive anticoagulant therapy * receive immunosuppression therapy * presence of coagulation disorders, such as platelet count less than 100,000 at the time of the joint evaluation, absolute neutrophil count less than 1,500 / ml * presence of signs of systemic infection * renal failure, creatinine clearance less than 45 ml/min confirmed with glomerular filtration less than 45 ml / min; evidence of unilateral renal exclusion * patients with uncontrolled metabolic disease

Keywords: curcumin natural antioxidant
anticoagulation in patients with venous thromboembolism and cancer

Conditions: Neoplasms; Embolism

Summary: this study is a retrospective analysis of observational cohorts using data from prospectively collected administrative/claims data to investigate treatment patterns,healthcare resource utilisation (hcru), direct and indirect costs (where feasible), and safety and effectiveness outcomes in patients with vte and active cancer or patients with vte and history of cancer who initiate anticoagulant treatment with a vka, lmwh or noacs.


Eligibility criteria:
inclusion criteria: * a vte diagnosis * active cancer or history of cancer * treatment with vka, noac (apixaban, rivaroxaban, dabigatran, edoxaban) or lmwh * age ≥ 18 years at the date of index vte (venous thromboembolic) exclusion criteria: * prior vte diagnosis * diagnosis of prior atrial fibrillation * inferior vena cava (ivc) filter * prior exposure to (oac) oral anticoagulation or (pac)parenteral anticoagulation - note: prophylactic use of (oac)/(pac) allowed. * pregnancy * more than one (oac) oral anticoagulation or (pac) parenteral anticoagulation dispensed on the index date. * patients with less than one day of follow up

Keywords: venous thromboembolism eliquis neoplasms anti-coagulation
effectiveness of two types of fixed lingual retainers in preventing mandibular incisor relapse

Conditions: Relapse

Summary: the study evaluates effectiveness of two types of fixed retainers in post orthodontic patients. half of the subjects are randomly allocated group 1 retainer (frc) and other half is given group 2 retainer (msw) and followed for a period of one year.

54 subjects were recruited and divided into two groups by random allocation. consents were obtained . group 1 received fiber reinforced composite retainer and group 2 received multistranded stainless steel wire retainer. the patients were recalled at every three months interval for a period of 12 months. they were evaluated for number of fractures, failure pattern based on adhesive remnant index and relapse tendency by measuring little's irregularity index.

Eligibility criteria:
inclusion criteria: * subjects who have completed fixed appliance orthodontic treatment. * subjects who have signed the consent forms. * subjects who have accepted the terms and conditions of visiting after every three months for one year. * non extraction cases in the mandibular arch with no ipr. * patients without caries/ restoration/ fracture on the lower anterior teeth. * patients with healthy periodontium with no periodontal disease at that time. exclusion criteria: * presence of syndrome or systemic disease. * patients taking medications/ drugs. * patients with poor oral hygiene. * patients with congenitally absent/ missing anterior teeth in the mandibular arch. * patients with habit of clenching/ bruxism. * patients with history of betel nut chewing. * presence of occlusal interferences.

Keywords: fixed retainers alignment
value of pet-ct in radiation treatment planning for patients with esophageal cancer

Conditions: Esophageal Cancer

Summary: the respect study is intended to prospectively assess the impact of pet/ct on the delineation of target volumes and to estimate the proportion of recurrences that could possibly be prevented by the use of pet/ct-based target volume, instead of ct-based. patients will recieve radiotherapy using ct-based planning, but a pet/ct-based treatment plan will also be made. ct-based and pet/ct-based target volumes will be compared after treatment has been completed. if a locoregional recurrence takes place, the localisation will be compared to the ct-based and pet/ct based clinical target volumes (ctvs). if the local recurrence is located outside the ct-ctv but inside the pet/ct-ctv, the recurrence could possibly have been prevented with pet/ct-based radiotherapy.

this is a prospective cohort study testing the hypothesis that in a proportion of patients, locoregional recurrence, observed at 6, 12 or 18 months after treatment, can be prevented if pet/ct-based treatment planning was used instead of ct-based treatment planning alone. patients eligible for the study will undergo definitive radiotherapy with or without concomitant chemotherapy with planning-ct based target volumes, either or not followed by surgery. a planning-pet/ct will be made for research purposes only, and will be blinded for the treating physicians. this planning-pet/ct will not be used for actual treatment planning. in case of neoadjuvant chemoradiation the response on this therapy will be analysed at pathologic evaluation of the esophageal specimen. routine follow up will be carried out every 6 months, using ct. in case of no locoregional recurrence and/or metastases, patients will be followed up to 18 months for study evaluation. in case of distant metastases, patients will be censored if locoregional recurrence is excluded. when indicated, palliative treatment will be given. in case of (suspicion of) locoregional recurrence, pet/ct-based recurrence analysis should be carried out with comparison and co-registration of ct-based and pet/ct-based target volumes.

Eligibility criteria:
inclusion criteria:- histologically proven adenocarcinoma or squamous cell carcinoma of the esophagus or gej * locally curable disease without distant metastases (m1b is excluded) (tnm clinical classification uicc 7th edition) * planned for high dose radiotherapy with or without chemotherapy with or without surgery * age ≥ 18 years; * who performance status 0-2 * informed consent must be given according to ich/eu gcp, and national/local regulations exclusion criteria:- previous or concurrent malignancies (except basal cell carcinoma of the skin or in situ carcinoma of the cervix or superficial bladder cancer (pta)) in the past five years * previous treatment * evidence of serious active infections * any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule

Keywords: pet/ct esophageal cancer radiotherapy
video laryngoscopy versus direct laryngoscopy for nasotracheal intubation

Conditions: Congenital Heart Disease; Airway Complication of Anesthesia

Summary: the aim of this study is to perform a pilot study investigating the first attempt intubation success rate differing between video laryngoscope nasotracheal intubation and direct laryngoscope nasotracheal intubation. the study population will consist of 60 neonates and infants with congenital heart disease less than 1 year of age who need nasotracheal intubation during general anesthesia for cardiac procedures. standard nasotracheal intubation will be performed using either a video laryngoscope or direct laryngoscopy. neonates and infants will be randomly assigned (1:1) to standard video laryngoscopy (with one of the following systems: storz c-mac miller video laryngoscope, karl storz, tuttlingen, germany or mc grath video laryngoscope, medtronic, boulder,usa) or to direct laryngoscopy with one of the following blades: miller or macintosh (heine, hersching, germany).


Eligibility criteria:
inclusion criteria. * age less than 1 year * congenital heart disease * scheduled for cardiac surgery * planned postoperative icu stay exclusion criteria * nostrils not suitable for nasotracheal intubation * bleeding during dilation of nostrils

Keywords: endotracheal intubation
single-used versus multiple-used endotracheal suction catheters in mechanically ventilated icu patients

Conditions: Ventilator Associated Pneumonia

Summary: in low and middle-income countries, open endotracheal suction catheters are used multiple times to perform suctioning due to limited resources \[1,2\]. currently, there is limited evidence for using a new suction catheter for each suction pass, acknowledged in a review article of endotracheal suction procedures in paediatric populations \[3\]. additionally, the latest artificial airway suctioning practice guidelines published by the american association for respiratory care in 2022 did not mention any recommendations regarding suction catheter changing frequency \[4\]. the guidelines adopted a study conducted in 2001 which showed that reusing an open tracheal suctioning catheter is safe and cost effective \[5\]. therefore, the current evidence of reusing suctioning catheters remains unclear, which rationalize the reason why some resource limited intensive care units (icus) use the catheter multiple times during a 12-hour shift, and possibly explain the high ventilator associated pneumonia (vap) incidence in these icus \[1,2\]. therefore, this feasibility study will propose to explore whether single-used suction catheters or multiple used open endotracheal tracheal suctioning catheters flushed with chlorhexidine are associated with reduced vap incidence and its impact on mechanically ventilated patients.


Eligibility criteria:
inclusion criteria: * adult patients (aged ≥ 18 years old) who are admitted to the icu, intubated with an endotracheal tube and receiving mechanical ventilation support directly after intubation with an expected mechanical ventilation support of at least 48 hours. * all adults' patients meeting the above criteria whose relatives agree for them to be part of the study via deferred consent process exclusion criteria: * patients who have received already standard care at icu admission (the use of an endotracheal suction catheter multiple times during endotracheal suction procedures) * patients with contraindications to endotracheal suctioning procedure such as increased intracranial pressure, severe haemoptysis, and cerebrospinal fluid leaks. * patients who are previously intubated during the current hospital admission. * patients expected to receive mechanical ventilation less than 72 hours. * patients diagnosed with pneumonia at icu admission. * patients having a modified clinical pulmonary infection score (mcpis) of 5 or greater. * patients with atelectasis, ards, and pulmonary oedema. * patients known to be allergic to chlorhexidine. * patients whose family (next-of-kin) have not provided deferred consent within 48 hours after icu admission will be excluded and standard care will be provided.
reduced ct + anti-pd-1 as first line tx in vulnerable older adults w/adv <50% pd-l1 non-small cell lung cancer (nsclc)

Conditions: Non-Small Cell Lung Cancer; NSCLC; Advanced Non-Small Cell Lung Cancer; Metastatic Non Small Cell Lung Cancer

Summary: evaluate frequency of adverse events that lead to chemotherapy discontinuation in vulnerable older adults with recurrent/metastatic pd-l1 tps\<50% nsclc patients who receive reduced dose chemotherapy in combination with immunotherapy.

this is a single institution, single arm, open label phase 2 study in vulnerable or older adults (age ≥70) with recurrent or metastatic, histologically confirmed squamous cell carcinoma or non-squamous cell carcinoma of lung without driver mutation and pd-l1 tps \< 50% to evaluate safety and tolerability of reduced dose of chemotherapy and immunotherapy.

Eligibility criteria:
inclusion criteria: * histologically or cytologically confirmed diagnosis of non-small cell lung cancer (nsclc) (either squamous or non- squamous) * stage iv disease or have recurrent disease and not be candidates for curative treatment such as combined chemo-radiation * no previous line of treatment in the recurrent or metastatic setting. neoadjuvant or adjuvant treatment more than 6 months before enrollment is acceptable. * age 70 or meeting frailty definition or above at the date of signing informed consent * absence of driver mutations that have first line food and drug administration (fda) approved targeted therapy * pd-l1 tumor proportion score (tps) of less than 50% * eastern cooperative oncology group (ecog) ps of 0-3 * have measurable disease based on recist 1.1 as determined by the local site investigator/radiology assessment * absolute neutrophil count (anc) ≥ 1,000/μl * platelets ≥ 75,000/μl * hemoglobin (hgb) ≥ 8.0 g/dl (transfusion permitted) * total bilirubin ≤ 2 x institutional upper limit of normal (uln) * aspartate amino transferase (ast)serum glutamic-oxaloacetic transaminase (sgot) /alanine aminotransferase (alt)serum glutamic-pyruvic transaminase (sgpt) ≤ 5.0 × institutional uln * ability to understand and the willingness to sign a written informed consent document exclusion criteria: * participants with life expectancy of less than 3 months at the time of enrollment * has active autoimmune disease that has required systemic treatment in past 2 years (ie, with use of disease modifying agents, or immunosuppressive drugs) * diagnosis of interstitial lung disease * creatinine clearance of \<30 ml/min * symptomatic, untreated central nervous system (cns) disease or leptomeningeal disease. patients with asymptomatic or treated cns disease are eligible * required ongoing use of immunosuppressive medication, including steroids, with the following allowable exceptions: * doses less than or equal to the equivalent of prednisone 10 mg daily * short courses of steroids that are discontinued prior to enrollment * inhaled, intranasal and/or topical steroids * dexamethasone taper for treating vasogenic edema associated with cns disease

Keywords: non-small cell lung cancer, nsclc
effect of honey supplementation on serum leptin in malnourished infants and children

Conditions: Malnourished Infants and Childern

Summary: this study was a randomized single blinded case control prospective intervention study.

fifty infants and children of both sexes, aged 6 months to 3 years, with malnutrition were consecutively recruited from the nutrition clinic of the pediatric hospital, ain shams university. these patients were randomly assigned following a simple randomization procedure (computerized random numbers) to either the honey group (group 1) or the malnourished control group (group 2) with a 1:1 allocation ratio. each group consisted of 25 patients. an additional 25 healthy infants and children with the same age range and of both sexes were recruited from the outpatient pediatric clinic of ain shams university, egypt as a healthy control group (group 3). the inclusion criteria was in whom the under nutrition is caused by inadequate energy intake, while the exclusion criteria included markedly ill patients, and children with chronic or severe systemic illness or malabsorption disorders, chromosomal aberrations, inborn errors of metabolism and cerebral palsy. history taking with special emphasis on the dietetic history, history of any disease that might interfere with the nutrient intake or their use by the body and history of any acute or chronic illness. and full body examination which include anthropometric measurements weight, height and mid arm circumference. each patient in the intervention group or honey group or group 1 took oral honey in a dose of 2ml/kg/day for 8 weeks; the calculated dose of honey was dissolved in water with a ratio of 1: 3, respectively, and then ingested by the patient before breakfast.

Eligibility criteria:
inclusion criteria: simple malnutrition exclusion criteria: cancer, sepsis, endocrine disorders, neurologic disorders, diabetes mellitus, heart failure renal failure liver cell failure. malabsorption disorders, chromosomal aberrations, inborn errors of metabolism cerebral palsy .